EpiVario

EpiVario Inc. is an innovative biotechnology company focused on developing neuroepigenetic modulators to treat memory-related addiction and psychiatric disorders. Spun out of the Epigenetics Institute of the University of Pennsylvania, EpiVario targets a newly discovered epigenetic process crucial for long-term memory formation. The company’s proprietary small molecule inhibitor of ACSS2 modulates neuronal plasticity, offering a novel approach to treating conditions like PTSD and substance use disorders. EpiVario serves the healthcare market, particularly patients suffering from neuropsychiatric conditions. The business model revolves around research and development, with revenue generated through partnerships, grants, and eventual commercialization of their therapeutic solutions. Co-founders Dr. Shelley Berger and Dr. Philipp Mews are leaders in neuroepigenetics, and their groundbreaking research underpins the company's innovative treatments. Dr. Caryn Lerman, a clinical advisor since March 2021, brings additional expertise in psychiatry and behavioral science.

Keywords: neuroepigenetics, PTSD, addiction, ACSS2 inhibitor, memory modulation, psychiatric disorders, biotechnology, healthcare, innovation, University of Pennsylvania.